Exploration of the role of drug resistance-associated anoikis-related genes in HER2-Negative breast cancer through bioinformatics analysis

被引:0
作者
Wu, Yuanzhao [1 ]
Chen, Cong [1 ]
Jin, Zao [1 ]
Zheng, Kesi [1 ]
机构
[1] Wenzhou Med Univ, Wenzhou Peoples Hosp, Clin Inst 3, Dept Breast & Thyroid Surg, Wenzhou 325000, Peoples R China
关键词
HER2 negative breast cancer; Prognostic models; anoikis; Biomarkers; Immune microenvironment;
D O I
10.1016/j.bbrep.2025.101947
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aims: To explore the potential functions and impacts of anoikis-related genes (ARGs) in breast cancer chemotherapy and to construct a prognosis model for HER2-negative breast cancer (HNBC) based on drug resistancerelated ARGs. Background: Breast cancer remains a leading cause of cancer-related mortality, with HER2-negative subtypes exhibiting high rates of metastasis and recurrence. Standard treatments for HNBC include taxane- and anthracycline-based chemotherapies, which aim to mitigate recurrence and metastasis. Anoikis, a specialized form of programmed cell death, plays a pivotal role in maintaining tissue homeostasis by eliminating detached cells. Cancer cells often develop resistance to anoikis, enabling survival in adverse conditions and promoting tumor progression. Objective: To investigate the intersection of breast cancer drug resistance-related genes and anoikis-related genes (ARGs) and to assess their potential as biomarkers for HNBC. The study also aims to analyze differences in immune microenvironment and drug sensitivity among different prognosis score groups. Method: A bioinformatics approach was employed to identify the intersection of breast cancer drug resistancerelated genes and ARGs. A prognosis model for HNBC was developed based on these identified drug resistance-related ARGs. The study further examined differences in the immune microenvironment and drug sensitivity among different prognosis score groups. Result: A prognosis model for HNBC was successfully constructed based on drug resistance-related ARGs. The study identified significant differences in immune microenvironment and drug sensitivity across different prognosis score groups. Conclusion: The findings suggest that ARGs could be key in tailoring more effective therapeutic approaches for patients with HER2-negative breast cancer.
引用
收藏
页数:9
相关论文
共 31 条
[1]   Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights [J].
Anestis, Aristomenis ;
Zoi, Ilianna ;
Papavassiliou, Athanasios G. ;
Karamouzis, Michalis V. .
MOLECULES, 2020, 25 (02)
[2]   Vaspin accelerates the proliferation, invasion and metastasis of Triple-Negative breast cancer through MiR-33a-5p/ABHD2 [J].
Cao, Xin-Hui ;
Chen, Xiu ;
Yang, Kai ;
Wang, Ya-Lin ;
Liang, Ming-Xing ;
Fei, Yin-Jiao ;
Tang, Jin-Hai .
CANCER MEDICINE, 2023, 12 (04) :4530-4542
[3]   Anoikis resistance--protagonists of breast cancer cells survive and metastasize after ECM detachment [J].
Dai, Yalan ;
Zhang, Xinyi ;
Ou, Yingjun ;
Zou, Linglin ;
Zhang, Duoli ;
Yang, Qingfan ;
Qin, Yi ;
Du, Xiuju ;
Li, Wei ;
Yuan, Zhanpeng ;
Xiao, Zhangang ;
Wen, Qinglian .
CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
[4]   IGF1 and Insulin Receptor Single Nucleotide Variants Associated with Response in HER2-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without a Fasting Mimicking Diet (BOOG 2013-04 DIRECT Trial) [J].
de Gruil, Nadia ;
Bohringer, Stefan ;
de Groot, Stefanie ;
Pijl, Hanno ;
Kroep, Judith R. ;
Swen, Jesse J. .
CANCERS, 2023, 15 (24)
[5]   Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial [J].
Fehm, Tanja ;
Mueller, Volkmar ;
Banys-Paluchowski, Maggie ;
Fasching, Peter A. ;
Friedl, Thomas W. P. ;
Hartkopf, Andreas ;
Huober, Jens ;
Loehberg, Christian ;
Rack, Brigitte ;
Riethdorf, Sabine ;
Schneeweiss, Andreas ;
Wallwiener, Diethelm ;
Meier-Stiegen, Franziska ;
Krawczyk, Natalia ;
Jaeger, Bernadette ;
Reinhardt, Florian ;
Hoffmann, Oliver ;
Mueller, Lothar ;
Wimberger, Pauline ;
Ruckhaeberle, Eugen ;
Blohmer, Jens-Uwe ;
Cieslik, Jan-Philipp ;
Franken, Andre ;
Niederacher, Dieter ;
Neubauer, Hans ;
Pantel, Klaus ;
Janni, Wolfgang .
CLINICAL CHEMISTRY, 2024, 70 (01) :307-318
[6]   A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17) [J].
Fukada, Ippei ;
Ito, Yoshinori ;
Kondo, Naoto ;
Ohtani, Shoichiro ;
Hattori, Masaya ;
Tokunaga, Eriko ;
Matsunami, Nobuki ;
Mashino, Kohjiro ;
Kosaka, Taijiro ;
Tanabe, Masahiko ;
Yotsumoto, Daisuke ;
Yamanouchi, Kosho ;
Sawaki, Masataka ;
Kashiwaba, Masahiro ;
Kawabata, Hidetaka ;
Kuroi, Katsumasa ;
Morita, Satoshi ;
Ohno, Shinji ;
Toi, Masakazu ;
Masuda, Norikazu .
BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (03) :425-434
[7]   CASP6 predicts poor prognosis in glioma and correlates with tumor immune microenvironment [J].
Guo, Kai ;
Zhao, Jiahui ;
Jin, Qianxu ;
Yan, Hongshan ;
Shi, Yunpeng ;
Zhao, Zongmao .
FRONTIERS IN ONCOLOGY, 2022, 12
[8]   Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer [J].
Hayashi, Yuji ;
Takei, Hiroyuki ;
Saito, Tsuyoshi ;
Kai, Toshihiro ;
Inoue, Kenichi ;
Kurosumi, Masafumi ;
Ninomiya, Jun .
JOURNAL OF NIPPON MEDICAL SCHOOL, 2021, 88 (04) :354-360
[9]   Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells [J].
Hong, Kyung U. ;
Tagnedji, Afi H. ;
Doll, Mark A. ;
Walls, Kennedy M. ;
Hein, David W. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (08) :5047-5060
[10]   The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status [J].
Jiang, Mingxia ;
Liu, Jiaxuan ;
Li, Qiao ;
Xu, Binghe .
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (07) :1324-1336